The Asia Pacific Testosterone Replacement Therapy Market would witness market growth of 5.0% CAGR during the forecast period (2024-2031).
The China market dominated the Asia Pacific Testosterone Replacement Therapy Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $158.8 million by 2031. The Japan market is registering a CAGR of 4.3% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 5.7% during (2024 - 2031).
Individuals with HIV/AIDS may experience muscle wasting and weight loss, known as HIV/AIDS-related wasting syndrome. Testosterone deficiency is common in individuals with HIV/AIDS and may contribute to muscle loss and reduced quality of life. TRT may be used as supportive therapy to increase muscle mass, improve strength, and enhance overall well-being in individuals with HIV/AIDS-related wasting syndrome.
Additionally, the adoption of testosterone replacement therapy has seen significant growth over recent years, driven by various factors. For example, patient advocacy groups and online communities have played a vital role in empowering individuals with hypogonadism to seek appropriate medical care and advocate for their healthcare needs. Through education, support, and information-sharing, these groups have helped reduce stigma, foster community engagement, and promote patient-centered care in the management of hypogonadism and other hormonal disorders.
As the population in China ages, there is a higher prevalence of age-related conditions such as hypogonadism. According to the State Council of the People’s Republic of China, Chinese citizens aged 60 or older comprise 18.7 percent of the nation’s total population, an increase of 5.44 percentage points since the last census conducted in 2010. Hence, the region’s growing elderly population and increasing healthcare industry are fuelling the market’s expansion.
Based on End User, the market is segmented into Clinics, and Hospital. Based on Product Type, the market is segmented into Injectables, Topical, and Others. Based on Active ingredients, the market is segmented into Testosterone Cypionate, Testosterone Undecanoate, Testosterone Enanthate, Testosterone, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Australia, and Rest of Asia Pacific.
The China market dominated the Asia Pacific Testosterone Replacement Therapy Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $158.8 million by 2031. The Japan market is registering a CAGR of 4.3% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 5.7% during (2024 - 2031).
Individuals with HIV/AIDS may experience muscle wasting and weight loss, known as HIV/AIDS-related wasting syndrome. Testosterone deficiency is common in individuals with HIV/AIDS and may contribute to muscle loss and reduced quality of life. TRT may be used as supportive therapy to increase muscle mass, improve strength, and enhance overall well-being in individuals with HIV/AIDS-related wasting syndrome.
Additionally, the adoption of testosterone replacement therapy has seen significant growth over recent years, driven by various factors. For example, patient advocacy groups and online communities have played a vital role in empowering individuals with hypogonadism to seek appropriate medical care and advocate for their healthcare needs. Through education, support, and information-sharing, these groups have helped reduce stigma, foster community engagement, and promote patient-centered care in the management of hypogonadism and other hormonal disorders.
As the population in China ages, there is a higher prevalence of age-related conditions such as hypogonadism. According to the State Council of the People’s Republic of China, Chinese citizens aged 60 or older comprise 18.7 percent of the nation’s total population, an increase of 5.44 percentage points since the last census conducted in 2010. Hence, the region’s growing elderly population and increasing healthcare industry are fuelling the market’s expansion.
Based on End User, the market is segmented into Clinics, and Hospital. Based on Product Type, the market is segmented into Injectables, Topical, and Others. Based on Active ingredients, the market is segmented into Testosterone Cypionate, Testosterone Undecanoate, Testosterone Enanthate, Testosterone, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Australia, and Rest of Asia Pacific.
List of Key Companies Profiled
- Endo International PLC
- AbbVie, Inc.
- Pfizer, Inc.
- Eli Lilly And Company
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
- Ferring Holdings SA
- Marius Pharmaceuticals LLC
- Besins Healthcare Monaco S.A.M.
- Acrux Limited
Market Report Segmentation
By End User- Clinics
- Hospital
- Injectables
- Topical
- Others
- Testosterone Cypionate
- Testosterone Undecanoate
- Testosterone Enanthate
- Testosterone
- Others
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Testosterone Replacement Therapy Market by End User
Chapter 5. Asia Pacific Testosterone Replacement Therapy Market by Product Type
Chapter 6. Asia Pacific Testosterone Replacement Therapy Market by Active ingredients
Chapter 7. Asia Pacific Testosterone Replacement Therapy Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Endo International PLC
- AbbVie, Inc.
- Pfizer, Inc.
- Eli Lilly And Company
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
- Ferring Holdings SA
- Marius Pharmaceuticals LLC
- Besins Healthcare Monaco S.A.M.
- Acrux Limited
Methodology
LOADING...
